Clinical Trial Update: A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease [Phase 1]

View source ↗

Summary

A Phase 1 study of RO5083945 in combination with cisplatin and gemcitabine or carboplatin and paclitaxel for squamous non-small cell lung cancer was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• PACLITAXEL (PACLITAXEL)
• RO5083945

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 1 | Status: WITHDRAWN